Search

一種新型利器盒的設計及應用

后疫情時代遠程教育提升癲癇診治水平的實踐與思考

自新型冠狀病毒肺炎（Corona virus disease 2019，COVID-19）疫情爆發以來，癲癇患者的身心健康受到了不同程度的影響。在后疫情時代，進一步提高癲癇診治水平的重要性不言而喻。在疫情防控形勢仍然嚴峻的當下，遠程教育憑借其開放性、延伸性、靈活性、管理性等特點成為這一特殊時期醫學教育的重要途徑。本文就后疫情時代遠程教育提升癲癇診治水平的實踐進行探討，并對未來遠程教育的發展予以思考。

新型血小板聚集功能缺陷癥并眼底出血二例

報告2例新型血小板聚集功能缺陷癥所致的眼底出血，用AP方案治療有效。討論了出血的機制，認為本病眼底出血同全身出血傾向一樣，與血小板膜糖蛋白Ⅲa位點上刺參酸性粘多糖受體被某種輔因子遮蔽有關。 （中華眼底病雜志，1994，10：176-177）

Practice of infection management in a large-scale mobile air capsule construction laboratory for severe acute respiratory syndrome coronavirus 2 nucleic acid detection

As an important tool for nucleic acid detection of variant strains of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), the mobile air capsule construction laboratory is a key medical resource in the prevention and control of COVID-19. Medical staff, security guards, cleaners, maintenance workers and volunteers in the mobile air capsule construction laboratory have high contact frequency with the samples, so they have a high risk of infection with COVID-19. In order to reduce this risk, this article discusses the infection management measures in the aspects of wearing and taking off personal protective equipment, environmental health management, post use goods management, medical waste management, staff training management and disposal process after occupational exposure, and analyzed the common problems in operation, based on the operation process of Nanchong mobile air capsule construction laboratory. The purpose is to provide a reference for the construction and management of other mobile air capsule construction laboratory.

Progress in the laboratory detection and clinical research of cryptococcosis

Cryptococcosis, mainly caused by Cryptococcus neoformans/gattii species complexes, is a lethal infection in both immunosuppressive and immunocompetent populations. With the upgrade of detection methods and the increase of clinical knowledge, the incidence rate of cryptococcosis is increasing, and it has become one of the most important fungi threatening human health. In recent years, great progress has been made in this field, including the taxonomy and nomenclature of Cryptococcus spp., laboratory diagnostic methods and antifungal susceptibility tests, as well as the characteristics and treatments of cryptococcosis. This article reviews the above contents, in order to improve the clinical and laboratory understanding of the Cryptococcus spp., and realize the timely diagnosis and early treatment of cryptococcosis.

A scoping review of clinical research evidence for traditional Chinese medicine in the treatment of coronavirus disease 2019

Objective To conduct a scoping review on the clinical research evidence for the treatment of coronavirus disease 2019 (COVID-19) with traditional Chinese medicine, identify relevant problems in the literature, and provide ideas for the follow-up research. Methods PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Digital Journal Full-text Database, and China Biomedical Literature Database were searched from inception to July 21st, 2022. The clinical research evidence for the treatment of COVID-19 with traditional Chinese medicine was included, the data information was sorted out, and the results were descriptively analyzed. Results A total of 132 studies were included, including 53 randomized controlled trials, 17 non-randomized controlled trials, and 62 retrospective cohort studies, all of which were published between 2020 and 2022. The clinical studies were carried out in 19 provincial level regions, among which Hubei province had the largest number of studies (49.2%, 65/132). The sample sizes of the studies were mostly between 50 and 100 cases (43.2%, 57/132). Most of the studies had a treatment course of 0-14 days (50.0%, 66/132). The most compared intervention measures were traditional Chinese medicine + conventional western medicine treatment vs. conventional western medicine treatment, accounting for 75.0% (99/132) of the studies. The COVID-19 patients included in the studies were mainly mild and moderate. Outcome indicators included changes in symptoms/signs, laboratory indicators, CT indicators, clinical outcomes, safety indicators, functional scales, etc. The main adverse reactions/events in intervention/exposure groups were gastrointestinal reactions. Conclusions There has been a lot of clinical research evidence on the treatment of COVID-19 by traditional Chinese medicine. To provide strong evidence support for the treatment of COVID-19 by traditional Chinese medicine, more clinical trials with large samples and international collaboration are needed in the future.

Prevention and control management standard of COVID-19 in the medical station of the medical team supporting for Hubei province from Sichuan province

To prevent and control 2019 novel coronavirus pneumonia diseases (COVID-19), hundreds of medical teams and tens of thousands of medical professionals throughout the nation were transferred to Hubei to assist COVID-19 control efforts. Medical professionals were at high risk of novel coronavirus pneumonia infections. To ensure the prevention and control of infection in medical teams and prevent cross-infection among medical staff at the medical station, this management standard includes routine management standards, resident disinfection, personnel entry and exit process, and logistics support management, so as to provide reference for medical teams combating COVID-19 in the future.

Efficacy and safety of the COVID-19 vaccine: a systematic review

ObjectiveTo systematically review the efficacy and safety of vaccines for the coronavirus disease 2019 (COVID-19) . Methods The CNKI, VIP, WanFang Data, PubMed, EMbase and Web of Science databases were electronically searched to collect randomized controlled trials (RCTs) on the safety and efficacy of COVID-19 vaccines from their inception to June 30th, 2022. Two reviewers independently screened the literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed using RevMan 5.3 software and Stata 12.0 software. Results A total of 13 RCTs involving 139 015 subjects were included. The results of meta-analysis showed that the sero-antibody conversion rate (RR=37.883, 95%CI 8.086 to 177.491, P<0.001) and infection prevention rate (RR=1.011, 95%CI 1.006 to 1.017, P<0.001) of the vaccine group were higher than those of the placebo group. The incidence of adverse reactions in the vaccine group was higher than that in the placebo group (OR=1.839, 95%CI 1.165 to 2.903, P=0.009), which mainly included pain, redness, swelling, fever, headache and itching (P<0.05). However, the incidence of serious adverse reactions was not significantly different from that of the placebo group. Conclusion The current evidence shows that the efficacy of the COVID-19 vaccines is high. The most prevalent adverse reactions are mild and moderate, and severe adverse reactions are the same as those of the placebo group. Due to the limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusion.

新型心臟停搏液灌注器在心肌保護中的應用

目的報告新型心臟停搏液灌注器在心肌保護中的應用。方法100例心臟病患者在心內直視術中采用自行設計制造的高鉀溫-冷-溫血心臟停搏液灌注器和新的高鉀氧合血配備方法進行心肌保護。結果體外循環時間31～163min，平均52.5min，主動脈阻斷時間11～112min，平均42.6min，心臟自動復跳率100％，均為竇性心律。結論自行設計的新型心臟停搏液灌注器和新的高鉀氧合血配備方法在心內直視手術中的心肌保護效果確切、滿意，有一定的臨床應用價值。

一種新型排線盤在心臟手術中的應用

目的 介紹一種新型排線盤在心瓣膜置換術中的應用。 方法 2009年5月至2010年6月，江蘇大學附屬武進人民醫院收治60例二尖瓣病變患者，男26例，女34例；年齡38～69歲(54.0±8.7歲)。所有患者均行二尖瓣置換術。將60例患者隨機分為兩組，每組30例。新型排線盤組：使用自行設計的新型排線盤（專利號:200920301200.5）；鋼絲排線盤組：使用傳統鋼絲彈簧排線盤；比較其各自性能，記錄并分析縫瓣時間、縫線脫落次數、縫線復位時間的差異。 結果 新型排線盤組患者縫瓣時間（13.20±0.72 min vs. 16.10±1.07 min, Plt;0.05）、縫線復位時間（2.50±0.61 s vs. 6.30±0.49 s, Plt;0.05）、縫線脫落次數（26次 vs. 93次,χ2=45.770，Plt;0.05) 短于或少于鋼絲排線盤組，兩組縫針數差異無統計學意義（365針 vs.362針, Pgt;0.05）。 結論 新型排線盤在心瓣膜置換術中的使用效果明顯優于傳統鋼絲彈簧排線盤。